Pozen

BOSTON (MarketWatch) -- Pozen Inc. /quotes/comstock/15*!pozn/quotes/nls/pozn  (POZN  10.83, -0.02, -0.18%)  shares sank 21% to $9.62 in early afternoon trading Friday. The FDA is expected to issue a decision on whether to approve its new arthritis medication Vimovo by the end of Friday. Vimovo was co-developed with AstraZeneca PLC /quotes/comstock/13*!azn/quotes/nls/azn  (AZN  44.35, +0.14, +0.31%) , shares of which were down marginally at $44.20.